natgillin/translations-raw huggingface dataset:
kaldede pletter i hårbunden, kulderystelser, hovedpine lavt immunforsvar, fordi indholdet af antistoffer i blodet, som beskytter mod infektion, kaldet immunglobuliner (IgG), falder.
bald spots on the scalp, chills, headache lower immunity – because of lower levels of anti-bodies called “immunoglobulins” (IgG) in the blood which help protect against infection.
kaldende hud
caling
Kaldes også vanddrivende tabletter og bruges til at øge urinproduktionen.
furosemide, a medicine belonging to the type known as diuretics, or “water” tablets, which is used to increase the amount of urine you produce.
Kaldes også vanddrivende tabletter, og bruges til at øge mængden af den urin, du producerer.
furosemide, a medicine belonging to the type known as diuretics, or “water” tablets, which is used to increase the amount of urine you produce.
kaldethed,
baldness,
Kalender til at følge din behandling og dit alkoholforbrug
Calendar to monitor your treatment and your alcohol consumption
Kalenderblister
CALENDAR BLISTER
KALENDERBLISTER
CALENDAR BLISTERS
KALENDERBLISTER
CALENDER BLISTER
KALENDERBLISTER (28x1 filmovertrukne tabletter)
CALENDER BLISTER (28x1 film-coated tablets)
KALENDERBLISTER (IKKE-PERFORERET) TEKST
CALENDAR BLISTER (NON-PERFORATED) TEXT
kalenderblister (PVC/PE/PVdC/alu)
calendar blister (PVC/PE/PVdC/alu)
Kalenderblister (PVC/PVDC/alu)
calendar blister (PVC/PVDC/alu)
kalenderblisterkort (alu/alu)
calendar blister (alu/alu)
KALENDERBLISTRE
CALENDAR BLISTER
kalenderdage
calendar
Kalenderdage
Calendar days Mon
Kalenderdage: Man., Tirs., Ons., Tors., Fre., Lør., Søn.
Calendar days: Mon., Tue.,Wed., Thu., Fri., Sat., Sun.
Kalenderpakning
CALENDAR BLISTERS
Kalenderpakning med perforerede blistere af aluminium-aluminium indeholdende 28x1 filmovertrukne tabletter.
Calendar pack of non-peelable blisters containing 28x1 tablets
Kalenderpakning med perforerede blistere af aluminium-aluminium indeholder 28x1 filmovertrukne tabletter.
Calendar pack of aluminium-aluminium perforated blisters contains 28x1film coated tablets.
Kaletra (80 mg+20 mg) / ml
Kaletra (80 mg + 20 mg) / ml
Kaletra 100 mg/25 mg film-overtrukne tabletter
Kaletra 100 mg/25 mg film-coated tablets
Kaletra 800/200 mg blev administreret i kombination med emtricitabin 200 mg og tenofovir DF 300 mg, som en del af et en- gang-daglig-regime.
Kaletra 800/200 mg was administered in combination with emtricitabine 200 mg and tenofovir DF 300 mg as part of a once-daily regimen.
Kaletra anbefales til voksne og børn på 2 år og derover, som har hiv.
Kaletra is recommended for use in adults and children 2 years of age or older who are infected with HIV.
Kaletra anvendes sammen med andre antivirale lægemidler til behandling af patienter over to år, som er smittet med humant immundefektvirus type 1 (hiv-1), som er et virus, der forårsager aids (erhvervet immundefektsyndrom).
Kaletra is used together with other anti-HIV medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Kaletra bør ikke anvendes til personer, der kan være overfølsomme (allergiske) over for lopinavir, ritonavir eller andre af indholdsstofferne.
Kaletra must not be used in people who are hypersensitive (allergic) to lopinavir, ritonavir or any of the other ingredients.
Kaletra er den anbefalede rifabutin-
Kaletra must not be
Kaletra er et lægemiddel, der indeholder to aktive stoffer, lopinavir og ritonavir.
Kaletra is a medicine that contains two active substances, lopinavir and ritonavir.
Kaletra er indiceret til behandling af humant immundefektvirus (hiv)-1-smittede voksne, unge og børn over 2 år i kombination med andre antiretrovirale stoffer.
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children above the age of 2 years, adolescents and adults.
Kaletra er indiceret til behandling af humant immundefektvirus (hiv-1)-smittede voksne, unge og børn over 2 år i kombination med andre antiretrovirale stoffer.
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.
Kaletra filmovertrukne tabletter er gule med påtrykt [Abbott-logo] og ”KA”.
Kaletra film-coated tablets are yellow embossed with [Abbott logo] and “KA”.
Kaletra filmovertrukne tabletter leveres også i pakninger, som indeholder 120 tabletter (1 plastik beholder á 120 tabletter) og multipakninger, som indeholder 3 plastik beholdere som indeholder 120 tabletter (360 tabletter).
Kaletra film-coated tablets are supplied in packs containing 120 tablets (1 plastic bottle of 120 tablets) and multipacks comprising 3 plastic bottles each containing 120 tablets (360 tablets).
Kaletra for at se, om justering af
stopping Kaletra, in order to see if
Kaletra forårsager sandsynligvis en stigning i plasmakoncentrationen af lægemidler, der fortrinsvis metaboliseres af CYP3A, .
Kaletra is likely to increase plasma concentrations of medicinal products that are primarily metabolised by CYP3A.
Kaletra fås også som 200 mg/50 mg film-overtrukne tabletter.
Kaletra is also supplied as 200 mg/50 mg film-coated tablets.
Kaletra helbreder ikke hiv-infektion eller aids, men kan forhale den beskadigelse af immunsystemet og de infektioner og sygdomme, der er forbundet med aids.
Kaletra does not cure HIV infection or AIDS, but it may delay the damage to the immune system, and the development of infections and diseases associated with AIDS.
Kaletra indeholder 42 % v/v alkohol og 15 % propylenglykol w/v.
Kaletra contains 42% v/v alcohol and 15% propylene glycol w/v.
Kaletra indeholder de aktive stoffer lopinavir og ritonavir.
Kaletra contains the active substances lopinavir and ritonavir.
Kaletra indeholder kalium som kaliumacesulfam, hvilket kan være skadeligt for personer på en diæt med lavt kalium indhold.
Kaletra contains potassium as acesulfame potassium, which may be harmful to people on a low potassium diet.
Kaletra indeholder lopinavir og ritonavir, der begge hæmmer CYP3A.
Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
Kaletra indeholder lopinavir og ritonavir, der begge hæmmer P450-isoformen CYP3A .
Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
Kaletra indeholder lopinavir og ritonavir, der begge hæmmer P450-isoformen CYP3A.
Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
Kaletra indgives oralt og bør altid tages sammen med mad (se punkt 5.2).
Kaletra is administered orally and should always be taken with food (see section 5.2)
Kaletra kan anvendes af børn fra 2 år, unge og voksne, der er smittet med hiv, som er den virus, der forårsager aids.
Kaletra is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS.
Kaletra må ikke administreres sammen med peroral midazolam (se pkt.
adjustment for midazolam should
Kaletra må ikke anvendes til patienter med svær leversygdom eller patienter, som tager perikum (en drogetilberedning til behandling af depression) eller lægemidler, der nedbrydes på samme måde som Kaletra, og som er skadelige i store mængder i blodet.
Kaletra must not be used by patients with severe liver disease or by patients who are taking St John’s wort (a herbal preparation used to treat depression) or medicines that are broken down in the same way as Kaletra and are harmful at high levels in the blood.
Kaletra må ikke gives til disse patienter. (se pkt 4.3).
Kaletra must not be given to these patients (see section 4.3).
Kaletra må ikke indgives en gang
Kaletra must not be administered
Kaletra må ikke indgives en gang
Kaletra must not be administered once daily in combination with efavirenz.
Kaletra må ikke tages en gang daglig med efavirenz, nevirapin, carbamazepin, phenobarbital og fenytoin.
Kaletra must not be taken once daily with efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.
Kaletra må ikke tages en gang daglig med efavirenz, nevirapin, carbamazepin, phenobarbital og phenytoin.
Kaletra must not be taken once daily with efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.
Kaletra nedsætter ikke risikoen for at smitte andre med hiv.
Kaletra does not reduce the risk of passing HIV to others.
Kaletra og colchicin er
Kaletra with colchicine in patients
Kaletra og telaprevir anbefales
fluvastatin or pravastatin is
Kaletra ordineres til brug i kombination med andre antivirale lægemidler.
Kaletra is prescribed for use in combination with other antiviral medicines.
Kaletra tabletter skal synkes hele, ikke tygges, deles eller knuses.
Kaletra tablets must be swallowed whole and not chewed, broken or crushed.
Kaletra, imens de tager
Kaletra while currently taking
Kaletra-dosis bør først titreres opad, når behandling med rifampicin er indledt (se pkt.
Kaletra is co-administered with
Kaletra-dosis er ikke nødvendig.
Kaletra must not be
Kaletra-tablet-dosis bør øges til
The Kaletra tablets dosage should
Kaletra-tabletter indgives oralt, skal synkes hele og ikke tygges, brækkes eller knuses.
Kaletra tablets are administered orally and must be swallowed whole and not chewed, broken or crushed.
Kaletra-tabletterne skal sluges hele og må ikke tygges, brækkes over eller knuses.
Kaletra tablets should be swallowed whole and not chewed, broken or crushed.
Kaletras hæmning af CYP3A4.
CYP3A4 inhibition by Kaletra.
Kaletras udseende og pakningsstørrelser
What Kaletra looks like and contents of the pack
Kaletras udseende og pakningstørrelse
What Kaletra look like and contents of the pack
Kaletras virkning (i kombination med andre antiretrovirale stoffer) på biologiske markører (plasma- hiv-RNA-niveauer og CD4+ T-celletælling) er blevet vurderet i kontrollerede studier med Kaletra af 48 til 360 ugers varighed.
The effects of Kaletra (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra of 48 to 360 weeks duration.
Kaletras virkning (i kombination med andre antiretrovirale stoffer) på biologiske markører (plasma- hiv-RNA-niveauer og CD4+ T-celletælling) er blevet vurderet i kontrollerede studier med Kaletra af 48 uger til 360 ugers varighed.
The effects of Kaletra (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra of 48 to 360 weeks duration.
Kalibreringstidspunkt: Klokkeslæt/dato
Calibration time: Time/Date
Kalibreringstidspunktet er sat mellem tidspunktet for afslut- ningen af syntesen og udløbstidspunktet.
The calibration time is set between the end of the synthesis time and the expiry time.
Kalium (Hyper)
Potassium (Hyper)
Kalium (Hypo)
Potassium (Hypo)
kalium i
Blood potassium
Kalium ≥ 3,5 mmol/l
Potassium ≥ 3.5 mmol/l
Kalium- og natriumindhold
Potassium and sodium contents
Kalium- og phosphatværdien i serum skal kontrolleres regelmæssigt under behandlingen med NeoRecormon.
Serum potassium and phosphate levels should be monitored regularly during NeoRecormon therapy.
kalium-besparende diuretika (se
sparing diuretics (see
kalium-besparende medicin eller andre vanddrivende midler
potassium sparing medicines or other diuretics (water tablets)
Kaliumaluminiumsilikat (E555) Titandioxid (E171)
Potassium aluminium silicate (E555) Titanium dioxide (E171)
Kaliumbesparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller anden medicin, som  øger kaliumniveauet
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels
kaliumbesparende diuretika, kaliumtilskud, salterstatninger, som indeholder kalium eller andre stoffer, der kan øge indholdet af kalium i blodet; en bestemt type smertestillende medicin, som kaldes non-steroide anti-inflammatoriske lægemidler (NSAID’er) eller selektive cyclooxygenase-2-hæmmere (COX-2-hæmmere).
potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; certain types of painkillers called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2 inhibitors).
kaliumbesparende medicin eller andre vanddrivende midler.
potassium sparing medicines or other diuretics (water tablets)
kaliumchlorid i en fast lægemiddelform, der tages gennem munden (se ovenstående punkt "Giv ikke Sialanar til barnet/den unge, hvis han/hun:")
potassium chloride solid oral dose (see section above “Do not give Sialanar if the child or adolescent:”)
Kaliumchlorid Kaliumdihydrogenphosphat Dinatriumphosphatdodecahydrat Vand til injektioner
Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injection
Kaliumchloridb (E508)
Potassium chlorideb (E508)
Kaliumdihydrogenphosphat (E340) Natriumhydroxid (E524)
Potassium dihydrogen phosphate (E340) Sodium hydroxide (E524)
Kaliumdihydrogenphosphat Dinatriumhydrogenphosphat Vand til injektionsvæsker
Potassium dihydrogen phosphate Disodium hydrogen phosphate Water for injections
Kaliumdihydrogenphosphat Dinatriumhydrogenphosphatdihydrat Natriumchlorid
Thiomersal Potassium chloride
Kaliumdihydrogenphosphat Dinatriumhydrogenphosphatdodecahydrat Natriumchlorid
Thiomersal Potassium chloride
Kaliumdihydrogenphosphat Dinatriumphosphatdodecahydrat Vand til injektioner
Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injection
Kaliumdihydrogenphosphat Dinatriumphosphatdodecahydrat Vand til injektionsvæsker
Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injection
Kaliumdihydrogenphosphat Dinatriumphosphatdodecahydrat Vand til injektionsvæsker
Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injections
Kaliumdihydrogenphosphat Natriumdihydrogenphosphathydrat Vand til injektionsvæske.
Potassium dihydrogen phosphate Disodium phosphate dehydrate Water for injection
Kaliumdihydrogenphosphat Vand til injektion.
Disodium phosphate dihydrate Potassium dihydrogen phosphate Water for injections
Kaliumdihydrogenphosphatc (E340i)
Potassium dihydrogen phosphatec (E340i)
Kaliumhydroxid (E525)
Potassium Hydroxide (E525)
Kaliumhydroxid4
Potassium Hydroxide4
Kaliumklorid Kaliumdihydrogenphosphat
Potassium chloride
Kaliumphosphat (monobasisk) Dinatriumphosphat heptahydrat
Magnesium sulphate heptahydrate Potassium phosphate monobasic Sodium phosphate dibasic heptahydrate
Kaliumsorbat Sorbitol (E 420) Renset vand
Potassium sorbate Sorbitol E420 Purified water
Kaliumsorbat Sorbitol E420 Renset vand
Potassium sorbate Sorbitol E420 Purified water
kaliumsparende medicin (som visse vanddrivende lægemidler) medicin, der indeholder lithium
potassium-sparing medicines (such as certain diuretics) medicines containing lithium
kaliumsparende medicin (som visse vanddrivende lægemidler) medicin, der indeholder lithium.
potassium-sparing medicines (such as certain diuretics) medicines containing lithium
kaliumsparende medicin (som visse vanddrivende lægemidler) medicin, der indeholder lithium.
potassium-sparing medicines (such as certain diuretics), medicines containing lithium.
kaliumtilskud
potassium supplements
kaliumtilskud
potassium supplements,
Kaliumtilskud og kalium-besparende diuretika
Potassium supplements and potassium-sparing diuretics
Kalktab fra knoglerne (med knoglesmerter, som nogle gange resulterer i knoglebrud), som kan forekomme på grund af beskadigelse af de tubulære celler i nyrerne
oftening of the bones (with bone pain and sometimes resulting in fractures) which may occur due to damage to the kidney tubule cells fatty liver
Kalktab fra knoglerne (med knoglesmerter; kan nogle gange resultere i knoglebrud)
Softening of the bones (with bone pain and sometimes resulting in fractures)
kalktab fra knoglerne (med knoglesmerter; kan nogle gange resultere i knoglebrud), som kan forekomme på grund af skader på celler i nyrerne (de tubulære celler)
softening of the bones (with bone pain and sometimes resulting in fractures), which may occur due to damage to kidney tubule cells
Kalktilskud og/eller D-vitamintilskud.
Calcium supplements and/or vitamin D supplements.
Kalkuner EU/2/04/044/015 – 40 g EU/2/04/044/016 – 400 g
Turkeys EU/2/04/044/015 – 40 g EU/2/04/044/016 – 400 g
Kalkuner: Må ikke anvendes i 21 dage før æglægningens begyndelse.
Turkeys: do not use within 21 days of the onset of lay.
Kalkuner: Én dosis af vaccinen fra dag 1 efterfulgt af anden dosis efter 3 uger ved administration af grov spray.
Turkeys: One dose of vaccine from 1 day of age followed by a second dose of vaccine 3 weeks later by coarse spray administration.
Kalkunherpesvirusset i vaccinen er modificeret, så det producerer det fusionsprotein, der danner den ydre kapsel af Newcastle disease-virus.
The turkey herpesvirus in the vaccine has been modified so that it will produce the fusion protein which forms part of the outer coat of ND virus.
Kaloriemålet er det maksimale antal kalorier du bør spise hver dag.
The calorie target is the maximum number of calories you will eat each day.
Kalvene skal gives tilstrækkelig kolostrum i følge god landmandspraksis.
The animals should receive enough colostrum according to good breeding practice.
Kalydeco
Kalydeco Kalydeco
Kalydeco 150 mg filmovertrukne tabletter ivacaftor
Kalydeco 150 mg film-coated tablets ivacaftor
Kalydeco 150 mg tabletter ivacaftor
Kalydeco 150 mg tablets ivacaftor
Kalydeco 50 mg granulat i brev ivacaftor
Kalydeco 50 mg granules in sachet ivacaftor
Kalydeco 50 mg granulat i brev Kalydeco 75 mg granulat i brev
Kalydeco 50 mg granules in sachet Kalydeco 75 mg granules in sachet
Kalydeco 50 mg granulat i brev Kalydeco 75 mg granulat i brev Ivacaftor
Kalydeco 50 mg granules in sachet Kalydeco 75 mg granules in sachet Ivacaftor
Kalydeco 50 mg granulat ivacaftor
Kalydeco 50 mg granules ivacaftor
Kalydeco 75 mg granulat ivacaftor
Kalydeco 75 mg granules ivacaftor
Kalydeco anvendes til behandling af cystisk fibrose hos patienter i alderen to år og derover, som har en ud af ni mutationer i genet for proteinet CFTR ("cystic fibrosis transmembrane conductance regulator").
Kalydeco is used to treat cystic fibrosis in patients aged 2 years and above who have one of nine mutations in the gene for the protein called ‘cystic fibrosis transmembrane conductance regulator’ (CFTR).
Kalydeco blev påvist at være effektivt til at forbedre lungefunktionen hos patienter med cystisk fibrose, som havde G551D-mutationen.
Kalydeco was shown to be effective at improving lung function in patients with cystic fibrosis who had the G551D mutation.
Kalydeco blev sammenlignet med placebo i to hovedundersøgelser, hvori der deltog 219 patienter med cystisk fibrose, som havde mutationen G551D.
Kalydeco was compared with placebo in two main studies involving 219 patients with cystic fibrosis who had the G551D mutation.
Kalydeco bør kun anvendes ved amning, hvis de mulige fordele opvejer de mulige risici.
Kalydeco should only be used during breast-feeding if the potential benefit outweighs the potential risk.
Kalydeco bør kun ordineres af læger med erfaring i behandling af cystisk fibrose og kun til patienter, som vides at have en af de ti ovennævnte mutationer.
Kalydeco should only be prescribed by doctors with experience in the treatment of cystic fibrosis, and only patients confirmed to have one of the ten mutations mentioned above should be prescribed the medicine.
Kalydeco er et lægemiddel, der indeholder det aktive stof ivacaftor.
Kalydeco is a medicine that contains the active substance ivacaftor.
Kalydeco er også indiceret til behandling af patienter med cystisk fibrose (CF) i alderen 18 år og derover, som har en R117H-mutation i CFTR-genet.
Kalydeco is also indicated for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene.
Kalydeco gives altid i kombination med de lægemidler, dit barn normalt bruger.
Kalydeco is always given in combination with the medicines your child usually uses.
Kalydeco gives altid i kombination med de lægemidler, du normalt bruger.
Kalydeco is always given in combination with the medicines you usually use.
Kalydeco har vist sig effektivt til at forbedre lungefunktionen hos patienter i alderen seks år og derover, som har en af ni CFTR-gating-mutationer, og hos patienter i alderen 18 år og derover, som havde en R117H-mutation.
Kalydeco has been shown to improve lung function in patients aged six years and above who had one of nine CFTR gating mutationsandin patients aged 18 years and above who had an R117H mutation.
Kalydeco indeholder lactose
Kalydeco contains lactose
Kalydeco kan også påvirke den måde, nogle andre lægemidler virker på.
Kalydeco can also affect how some other medicines work.
Kalydeco kan også påvirke, hvordan andre lægemidler virker.
Kalydeco can also affect how some other medicines work.
Kalydeco skal tages sammen med fedtholdig mad.
Kalydeco should be taken with fat-containing food.
Kalydeco var også effektivt hos patienter med andre mutationer end G551D.
Kalydeco was also effective in patients with mutations other than G551D.
Kalydeco-granulat anvendes til behandling af børn med cystisk fibrose (CF) i alderen 2 år og derover, der vejer mindre end 25 kg, og som har en af de følgende gating-mutationer i CFTR-genet: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549 eller S549R.
Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25 kg who have one of the following gating mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Kalydeco-tabletter anvendes til behandling af patienter med cystisk fibrose (CF) i alderen 6 år og derover, der vejer 25 kg eller mere, og som har en af de følgende gating-mutationer i CFTR-genet: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549 eller S549R.
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Kalydeco-tabletter er ikke egnet til børn under 6 år.
Kalydeco tablets are not adequate for children under 6 years of age.
Kalydeco: 75 mg granulat i brev ivacaftor
Kalydeco 75 mg granules in sachet ivacaftor
Kalydecos sikkerhed og virkning hos børn under 2 år er ikke klarlagt.
The safety and efficacy of Kalydeco in children aged less than 2 years have not been established.
Kalydecos sikkerhed og virkning hos børn under 2 år med en gating (klasse III)-mutation er ikke klarlagt.
The safety and efficacy of Kalydeco in children aged less than 2 years with a gating (class III) mutation have not been established.
Kalydecos virkning er blevet evalueret i to fase 3 randomiserede, dobbeltblinde, placebokontrollerede multicenter-studier med klinisk stabile patienter med CF, som havde G551D-mutationen i CFTR-genet på mindst 1 allel, og havde FEV1 ≥40 % af forventet værdi.
The efficacy of Kalydeco has been evaluated in two Phase 3 randomised, double-blind, placebo-controlled, multi-centre studies of clinically stable patients with CF who had the G551D mutation in the CFTR gene on at least 1 allele and had FEV1 ≥40% predicted.
Kammer
ed sed
Kammer og mundstykke – 1 gang om ugen
Chamber and mouthpiece – once a week
Kammer- frigivelsesknap
Grey Button
kan anvendes samtidigt
co-administered without dose
kan anvendes uden
can be used without dose
Kan anvendes under drægtighed
Can be used during pregnancy.
Kan anvendes under drægtighed og laktation
Can be used in pregnancy and lactation
Kan anvendes under drægtighed og laktation Overdosering
Can be used during pregnancy and lactation Overdose:
Kan anvendes under drægtighed og laktation.
Can be used during pregnancy and lactation
Kan anvendes under drægtighed og laktation.
The vaccine can be used during pregnancy and lactation.
Kan anvendes under drægtighed og laktation.
This vaccine can be used during pregnancy and lactation.